ClinicalTrials.gg
RecruitingNCT07609394Updated Nov 2, 2026

Duchenne Electronic Health Record Study

An observational study in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy and Dystrophinopathy, sponsored by The Duchenne Registry. Recruiting at 11 sites in United States. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by The Duchenne Registry · Observational

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.
Updated Nov 2, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
2,500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Planned enrollment
4th of 55
2,500 · median 75
Started
2022
with 14 others
Observational
55 of 233
16 open now
Primary completion
2035-12
later than 59 of 59 live
Registered
227th of 233
by date

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 4th largest by planned enrollment of the 55 observational ones that give a count, is one of 15 that started in 2022, is one of 55 observational ones, reaches primary completion later than 59 of the 59 other live ones, and was the 227th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

This study aims to collect retrospective and prospective, long-term data of patients with dystrophinopathy (including Duchenne, Becker, and female carriers) through electronic transfer. At select clinics across the United States, electronic health record (EHR) data from consented patients will be pushed into PPMD's Duchenne Outcomes Research Interchange (the Interchange), where the EHR data can be combined with patient-reported data from The Duchenne Registry. By combining this data in a central hub, we will gain a more complete picture of Duchenne and Becker muscular dystrophy, allowing researchers and clinicians to develop treatments faster and to improve and refine the standards of care for Duchenne and Becker. The ultimate goal is to optimize function, quality of life, and survival of Duchenne and Becker patients.

EHR data collected will be fully identifiable retrospective data for core clinical data elements going back ten years (as available) from the date of consent; going back one year for retrospective clinical notes from the date of consent; and prospectively collecting both core clinical data elements and clinical notes. Information collected will align with the FHIR U.S. core data elements, also known as the Common Clinical Data Set.

PPMD partnered with Prometheus Research (an IQVIA company), an industry leader in health data informatics, to launch both the EHR Study and the Interchange. All data is stored securely and in accordance with strict industry standards and patient privacy laws. Participation in the EHR data extraction is voluntary, and a patient can withdraw consent at any time.

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)
  • Becker Muscular Dystrophy
  • Dystrophinopathy
  • Dystrophinopathy Symptomatic Female Carrier

Keywords

  • Duchenne
  • Becker
  • Dystrophinopathy
  • Muscular Dystrophy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with dystrophinopathy (including Duchenne, Becker, and carriers) who are patients at a Certified Duchenne Care Center (CDCC) in the United States that has an established EHR integration with PPMD's Interchange.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Duchenne or Becker muscular dystrophy or female carrier
  • Must be a patient at an institution that has an established EHR integration set up with PPMD's Interchange
  • Must provide consent to have their EHR data pushed to the Interchange and linked to existing Registry data, if applicable

Exclusion criteria

Exclusion Criteria:

  • Individuals with other forms of muscular dystrophy
  • Individuals who do not provide consent

Individuals with Duchenne/Becker who have severe mobility/strength issues need to provide consent and participate with assistance from a caregiver. Adults with communication impairments and/or intellectual disabilities (considered the "decisionally impaired" group for purposes of this study) will be able to consent with the assistance of the adults who are designated Legally Authorized Representative (LAR). Without assistance, this group will be excluded from participation because the consent process.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
2,500 participants (estimated)
Target follow-up
20 Years
Patient registry
Yes

Interventions

  • OtherObservational study with patients who may be treated with various disease-modifying therapies

    Patients may be on any combination of therapies to participate, including FDA-approved therapies (corticosteroids, exon skipping therapy, gene therapy) or therapies in clinical trial.

06

What researchers measure

Primary outcomes

  1. Progressive Muscle Weakness

    Characterize progressive muscle weakness in dystrophinopathy patients over time by measuring 1) age at start of corticosteroids (age at first prescription); 2) corticosteroid use including name, dose, regimen; and 3) dependence on wheelchair or age at fulltime wheelchair use (date of wheelchair/DME order).

    Time frame: Date of initiation of corticosteroids and date of first wheelchair/DME order; Steroid use recorded at baseline (day 1) and each annual follow-up visit (until patient is no longer seen at institution or withdraws consent), anticipated average of 20 years.

  2. Cardiac Function

    Characterize cardiac standard of care and cardiac function in dystrophinopathy patients by measuring 1) age at first echocardiogram, cardiac MRI, and EKG; 2) age at first ACE inhibitor or ARB prescription; and 3) recording LVEF on echocardiogram and cardiac MRI throughout study.

    Time frame: Date of first echo, cardiac MRI, and EKG and all follow-up scans recorded at each annual visit (until patient is no longer seen at institution or withdraws consent), anticipated average of 20 years; Date of first ACE inhibitor or ARB prescription.

  3. Pulmonary Function

    Characterize pulmonary standard of care and pulmonary function in dystrophinopathy patients by measuring spirometry results including 1) forced vital capacity (FVC), % predicted; and 2) peak cough flow (PCF) in L/min.

    Time frame: FVC and PCF recorded at baseline (day 1) and at each annual follow-up visit (until patient is no longer seen at institution or withdraws consent), anticipated average of 20 years.

  4. Bone Health

    Characterize orthopedic standard of care and bone health in dystrophinopathy patients by measuring 1) date of first Xray of spine and DEXA scan; 2) age at first bisphosphonates prescription; and 3) recording BMI throughout study.

    Time frame: BMI, Xray of spine and DEXA scan recorded at baseline (day 1) and at each annual follow up visit (until patient is no longer seen at institution or withdraws consent), anticipated average of 20 years; Date of first bisphosphonates prescription.

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified IDP may be shared with researchers following approval by the Duchenne Outcomes Research Interchange Steering Committee.

Supporting information: Study protocol, Informed consent form

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2035, 156 months after the start.

Of 52 non-industry observational studies under Muscular Dystrophy, Duchenne, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 120. This study's planned 156 months is above that.

Counting every sponsor, half of 63 studies reached it within 40 months; a quarter within 12 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
May 27, 2026
StartActual
Dec 1, 2022
Primary completionEst.
Dec 2035
CompletionEst.
Dec 2072
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. UC Davis Health is now Recruiting
Show site
  • Seattle Children's Hospital · Seattle, United States
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added. UC Davis Health is now Recruiting
    Show site
    • Seattle Children's Hospital · Seattle, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07609394
Lead sponsor
The Duchenne Registry
Collaborators
Parent Project Muscular Dystrophy
Responsible party
Sponsor
First posted
May 27, 2026
Start date
Dec 1, 2022
Primary completion
Dec 2035 (estimated)
Completion
Dec 2072 (estimated)
Last update
Nov 2, 2026

Study contacts

Megan Freed, MPH
Contact
megan@parentprojectmd.org
800-714-5437
Ann Martin, MS, CGC
Contact
ann@parentprojectmd.org
800-714-5437
Ann Martin, MS, CGC
principal investigator · Parent Project Muscular Dystrophy
Eric Camino, PhD
principal investigator · Parent Project Muscular Dystrophy
Rachel Schrader, MS, APRN, CPNP-PC
principal investigator · Parent Project Muscular Dystrophy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion